CAO Group has filed patent infringement lawsuits in the United States District Court for the State of Utah and in the United States District Court for the Central District of California against Biolase. CAO will open the stayed case in Utah Federal Court and file an amendment for infringement of reexamined US Patent 7,485,116 C1 against Biolase’s EPIC and ezlase product lines.
Biolase challenged the original US Patent 7,485,116 through inter partes reexamination after CAO filed its complaint in 2012. CAO received the reexamination certificate in July 2017, affirming the patentability of four claims added to the patent during the reexamination.
Also, CAO filed a patent infringement complaint in California Federal County identifying Biolase’s infringement of claims in CAO’s US Patents 8,337,097, 8,834,457, 8,961,040, and 8,967,883 by its EPIC, iLase, and exlase product lines. CAO is seeking past damages, injunction relief, enhanced damages for willful infringement, and legal costs in both cases.
“Biolase Inc knows of CAO’s patents, failed the challenge of CAO’s key patent through reexamination in the US patent and trademark office, and continues to infringe CAO’s patents by marketing and selling infringing diode laser products. All of Biolase’s diode laser products are covered by CAO’s issued patents. CAO will vigorously defend its technology to protect its investment and licensed manufacturers,” said Densen Cao, PhD, CAO president.
Related Articles
High-Power Diode Laser Gets FDA Approval
